

Accepted Manuscript

Title: Molecular targets and pathways for the treatment of visceral leishmaniasis

Authors: Vineet Jain, Keerti Jain

PII: S1359-6446(17)30076-4

DOI: <http://dx.doi.org/10.1016/j.drudis.2017.09.006>

Reference: DRUDIS 2080

To appear in:



Please cite this article as: Jain, Vineet, Jain, Keerti, Molecular targets and pathways for the treatment of visceral leishmaniasis. Drug Discovery Today <http://dx.doi.org/10.1016/j.drudis.2017.09.006>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Molecular targets and pathways for the treatment of visceral leishmaniasis

Vineet Jain¹ and Keerti Jain^{1,2}

¹National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, India

¹Current address: Faculty of Pharmacy, The Maharaja Sayajirao University (MSU) of Baroda, Vadodara, India

Corresponding author: Jain, K. (keertijain02@gmail.com)

Teaser: Visceral leishmaniasis is a complicated disease that can be fatal if left untreated. To improve its treatment protocol, comprehensive investigations of biomolecular targets and/or pathways that can modify the disease are required.

Highlights

- Visceral leishmaniasis is a complicated infectious disease.
- Emerging resistance is one of the main complications in treatment visceral leishmaniasis.
- A comprehensive investigation of biomolecular targets/pathways is required.
- Ornithine decarboxylase and trypanothione reductase could be important druggable targets.

Visceral leishmaniasis (VL) represents the most severe form of the tropical disease, leishmaniasis. Treatment of VL is complicated because of the few clinically approved antileishmanial drugs available; emerging resistance to first-line drugs; need for a temperature-controlled 'cold' supply chain; serious toxicity concerns over drugs such as Amphotericin B; high cost of medication; and unavailability of clinically approved antileishmanial vaccines. Attacking potential molecular targets, specific to the parasite, is a vital step in the treatment of this and other infectious diseases. As we discuss here, comprehensive investigation of these targets could provide a promising strategy for the treatment of visceral leishmaniasis.

Keywords: visceral leishmaniasis; amphotericin B; *Leishmania*; trypanothione reductase; molecular targets.

Introduction

Download English Version:

<https://daneshyari.com/en/article/8410113>

Download Persian Version:

<https://daneshyari.com/article/8410113>

[Daneshyari.com](https://daneshyari.com)